|
ABOUT COMPANY
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
|
EARNINGS
Gross Profit (TTM): 214000
Market Capitalization: 30179800
Operating Margin (TTM): -4.666
PE Ratio: None
PEG Ratio: 0
Profit Margin: 0
Revenue Per Share (TTM): 0.043
Revenue (TTM): 1010000
Quarterly Earnings Growth YOY: 0
Quarterly Revenue Growth YOY: 2.327
Trailing PE: -
|
DIVIDENDS
Diluted EPS (TTM): -0.549
Dividend Date: None
Dividend Per Share: None
Dividend Yield: 0%
EBITDA: -5785000
ExDividend Date: None
Forward Annual Dividend Rate:
Forward Annual Dividend Yield:
|